Snail-inspired drug protects mouse hearts in lab study

A hibernating snail has handed researchers a chemical clue to a major problem in organ transplantation. At the University of Alberta, Dr. Evangelos Michelakis and his team created SNAP, a drug modeled on a natural snail molecule, and used it to protect mouse hearts from damage when blood flow stopped and then returned.

That two-part injury is known as ischemia-reperfusion: tissue is deprived of oxygen, then stressed again as circulation comes back. Hibernating animals naturally tolerate it; humans do not. SNAP temporarily changes how cells consume oxygen, helping place the tissue into what the researchers describe as a deep metabolic sleep. The study also links its protection to metabolic rewiring and autophagy, the cell's process for clearing and recycling damaged material.

In experiments modeling the process in mouse hearts, the University of Alberta team found that SNAP prevented injury and preserved heart function. The work, led by Michelakis, was published in Nature Communications. The researchers describe it as a direct transfer of hibernation biology to a non-hibernating animal.

And concretely? If the effect holds beyond the laboratory, transplant teams could have a way to shield donated organs during transport from donor to recipient. That could make more offered organs usable. A related use could be protecting heart tissue during procedures that reopen blocked arteries after a heart attack. For patients, the possible benefit would be less damage when oxygen supply changes abruptly.

The distance to the clinic remains substantial. The reported evidence comes from mouse hearts, and no human treatment or clinical trial is described. SNAP may also be relevant to tumors, longevity medicine and even inducing hibernation in astronauts on very long space journeys, but those applications remain possibilities.